RZLT insider transaction filings
Rezolute, Inc. — 47 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-07. Screen RZLT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-07 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Tax withholding (F): 3,062 @ $4.99 | EDGAR |
| 2026-07-07 | 4 | Evans Daron — CFO | Tax withholding (F): 3,062 @ $4.99 | EDGAR |
| 2026-07-07 | 4 | Elam Nevan C — CEO, Director | Tax withholding (F): 8,004 @ $4.99 | EDGAR |
| 2026-03-31 | 4 | Evans Daron — CFO | Purchase (P): 10,000 @ $2.85 | EDGAR |
| 2026-03-04 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Tax withholding (F): 11,439 @ $2.99 | EDGAR |
| 2026-03-04 | 4 | Evans Daron — CFO | Tax withholding (F): 11,438 @ $2.99 | EDGAR |
| 2026-03-04 | 4 | Elam Nevan C — CEO, Director | Tax withholding (F): 27,618 @ $2.99 | EDGAR |
| 2025-12-17 | 4 | Hogenhuis Wladimir — Director | Purchase (P): 5,650 @ $1.69 | EDGAR |
| 2025-12-17 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Purchase (P): 28,000 @ $1.70 | EDGAR |
| 2025-12-15 | 4 | Karnawat Sunil Ratilal — Chief Commercial Officer | Purchase (P): 12,000 @ $1.62 · Purchase (P): 100 @ $1.60 | EDGAR |
| 2025-12-15 | 4 | Evans Daron — CFO | Purchase (P): 40,000 @ $1.77 · Purchase (P): 2,500 @ $1.78 · Purchase (P): 2,500 @ $1.79 | EDGAR |
| 2025-12-15 | 4 | Elam Nevan C — CEO, Director | Purchase (P): 32,000 @ $1.59 | EDGAR |
| 2025-11-21 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Grant/award (A): 123,000 @ $0 · Code (?): 72,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Karnawat Sunil Ratilal — Chief Commercial Officer | Grant/award (A): 32,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | KREHER NERISSA — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Hogenhuis Wladimir — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Harris Erik — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Kim Young-Jin — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | FAUCHET PHILIPPE — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Evans Daron — CFO | Grant/award (A): 107,000 @ $0 · Grant/award (A): 63,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Labrucherie Gil M — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Elam Nevan C — CEO, Director | Grant/award (A): 317,000 @ $0 · Grant/award (A): 186,000 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Karnawat Sunil Ratilal — Chief Commercial Officer | Grant/award (A): 25,000 @ $0 · Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Purchase (P): 2,500 @ $4.38 | EDGAR |
| 2025-06-24 | 4 | Evans Daron — CFO | Purchase (P): 5,000 @ $4.05 | EDGAR |
| 2025-06-23 | 4 | Kim Young-Jin — Director | Purchase (P): 1,230,769 @ $3.25 | EDGAR |
| 2025-06-23 | 4 | KREHER NERISSA — Director | Purchase (P): 3,076 @ $3.25 | EDGAR |
| 2025-06-13 | 4 | KREHER NERISSA — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Hogenhuis Wladimir — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Labrucherie Gil M — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Kim Young-Jin — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | FAUCHET PHILIPPE — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Grant/award (A): 26,000 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Evans Daron — CFO | Grant/award (A): 26,000 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Elam Nevan C — CEO, Director | Grant/award (A): 68,000 @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Hogenhuis Wladimir — Director | Purchase (P): 6,758 @ $2.92 | EDGAR |
| 2025-03-31 | 4 | Elam Nevan C — CEO, Director | Purchase (P): 12,302 @ $2.85 | EDGAR |
| 2025-03-28 | 4 | Evans Daron — CFO | Purchase (P): 10,000 @ $2.89 · Purchase (P): 10,000 @ $2.88 | EDGAR |
| 2025-03-26 | 4 | Harris Erik — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Hogenhuis Wladimir — Director | Grant/award (A): 25,500 @ $0 · Purchase (P): 10,000 @ $4.70 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Labrucherie Gil M — Director | Grant/award (A): 25,500 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | KREHER NERISSA — Director | Grant/award (A): 25,500 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Kim Young-Jin — Director | Grant/award (A): 25,500 @ $0 · Purchase (P): 1,250,000 @ $4 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Grant/award (A): 77,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | FAUCHET PHILIPPE — Director | Grant/award (A): 25,500 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Evans Daron — CFO | Grant/award (A): 77,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Elam Nevan C — CEO, Director | Grant/award (A): 204,000 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Rezolute, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-06-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RZLT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →